- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02868190
Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication
A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study design is as follows:
Prospective
Subjects with medicated IOP > 18 mmHg and ≤ 30 mmHg
Subjects on one topical ocular hypotensive medication prior to stent implantation
Implantation of two iStent devices (if IOP is < 6 mmHg, at any point during the postoperative follow-up, medication will not be prescribed or will be discontinued)
IOP will be measured by two (2) observers to minimize bias; observer 1 will look through the slit lamp and turn the dial with readings being masked, and observer 2 will document the IOP
Diurnal IOP measurements
Follow-up through 60 months postoperative (but could be up to 61 months if subject needs to undergo terminal washout)
Descriptive statistics will be tabulated
Medical therapy considered necessary for the subject's welfare can be implemented at any time during the study at the investigator's discretion
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Yerevan, Armenia, 375108
- S.V. Malayan's Ophtalmology Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
Screening Exam Inclusion Criteria:
- Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs).
- Primary open-angle glaucoma (including pigmentary or pseudoexfoliative).
- Cup-to-disc ratio ≤ 0.9.
- Visual field defects, or nerve abnormality characteristic of glaucoma.
- One topical hypotensive medication at time of screening exam.
- Intraocular pressure (IOP) > 18 mmHg and ≤ 30 mmHg (medicated) at screening exam.
- Study eye BCVA 20/100 or better.
- Normal angle anatomy as determined by gonioscopy.
- Absence of peripheral anterior synechia (PAS), rubeosis or other angle abnormalities that could impair proper placement of stent.
Baseline Exam Inclusion Criteria:
- Subject has completed appropriate medication washout.
- Mean IOP > 22 mmHg and ≤ 38 mmHg after anti-glaucoma medication washout period.
EXCLUSION CRITERIA:
Screening Exam Exclusion Criteria:
- Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs).
- Prior stent implantations (study eye).
- Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders.
- Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma.
- Prior incisional glaucoma surgery.
- Prior SLT within 90 days prior to screening.
- Prior ALT.
- Iridectomy or laser iridotomy.
- Ineligibility for ocular hypotensive medication washout period as determined by the investigator such as: visual field status would be placed at risk by washout period, or unmedicated IOP after washout period would be expected to exceed upper limit of ≥ 38 mmHg.
- Any active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis).
- Clinically significant corneal dystrophy (e.g., bullous keratopathy, Fuch's dystrophy); any guttata.
- Corneal surgery (prior or anticipated) of any type (including LASIK, LASEK, PRK, etc.) that may interfere with IOP measurement reliability.
- Corneal opacities or disorders that would inhibit visualization of the nasal angle.
- Congenital or traumatic cataract.
- Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition.
- Elevated episcleral venous pressure such as associated with: active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
- Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.).
- Chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis).
- Pregnant or nursing women.
Baseline Exam Exclusion Criteria:
- Subject did not complete medication washout.
- Mean IOP < 22 mmHg or > 38 mmHg after anti-glaucoma medication washout.
- Subject did not have a 3mmHg IOP increase over screening mean diurnal IOP.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Two micro-bypass stents (iStent inject)
Standalone implantation of two trabecular micro-bypass stents (iStent inject)
|
Standalone implantation of two trabecular micro-bypass stents (iStent inject)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean intraocular pressure reduction of 20% or more vs baseline
Time Frame: 12 months post-op
|
12 months post-op
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with intraocular pressure less than or equal to 18 mm Hg
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lilit Voskanyan, MD, PhD, S.V. Malayan Eye Center
Publications and helpful links
General Publications
- Lindstrom R, Lewis R, Hornbeak DM, Voskanyan L, Giamporcaro JE, Hovanesian J, Sarkisian S. Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. Adv Ther. 2016 Nov;33(11):2082-2090. doi: 10.1007/s12325-016-0420-8. Epub 2016 Oct 13.
- Lindstrom R, Sarkisian SR, Lewis R, Hovanesian J, Voskanyan L. Four-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication. Clin Ophthalmol. 2020 Jan 13;14:71-80. doi: 10.2147/OPTH.S235293. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCF-038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Angle Glaucoma
-
AllerganRecruiting18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)Ocular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
West Virginia UniversityUniversity of Pittsburgh; University of MichiganWithdrawnOpen-angle Glaucoma
-
Glaukos CorporationUnknownOpen-Angle GlaucomaSpain, Germany, Austria, Turkey
-
Alcon ResearchWithdrawnOpen-Angle Glaucoma
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Pharmaceutical Research NetworkCompleted
-
National Eye Institute (NEI)CompletedOpen-Angle Glaucoma
Clinical Trials on Two trabecular micro-bypass stents (iStent inject)
-
University of Turin, ItalyCompletedPrimary Open Angle Glaucoma and Cataracts
-
Glaukos CorporationCompletedGlaucoma | Glaucoma, Open-Angle | Eye DiseasesSpain, France, Armenia, Germany, Austria, Italy
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pseudoexfoliative Glaucoma | Pigmentary Dispersion GlaucomaUnited States
-
Glaukos CorporationCompleted
-
Glaukos CorporationCompletedOpen-Angle GlaucomaGermany, Spain, Turkey, Netherlands, Austria
-
Umeå UniversityRecruitingCataract | Open Angle Glaucoma | MIGS | Kahook Dual Blade Glide | Istent Inject W | GoniotomySweden
-
New World Medical, Inc.CompletedOpen Angle GlaucomaUnited States
-
Helsinki University Central HospitalRecruitingCataract | Exfoliation GlaucomaFinland
-
Glaukos CorporationActive, not recruiting